Comparative Pharmacology
Head-to-head clinical analysis: AMINOPHYLLIN versus VOSPIRE ER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOPHYLLIN versus VOSPIRE ER.
AMINOPHYLLIN vs VOSPIRE ER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective phosphodiesterase inhibitor, increasing intracellular cAMP and cGMP; adenosine receptor antagonist, causing bronchodilation, CNS stimulation, and positive chronotropic/inotropic effects.
Vospire ER (albuterol sulfate) is a beta2-adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing cyclic AMP production via activation of adenylyl cyclase, leading to bronchodilation.
Loading dose: 6 mg/kg IV over 30 minutes (if not on theophylline); maintenance: 0.5-0.7 mg/kg/hr IV continuous infusion for adults (non-smoking), higher for smokers (0.7-0.9 mg/kg/hr). Oral: immediate-release 200-400 mg every 6 hours; sustained-release 400-600 mg every 12 hours.
Oral: 30-60 mg once daily in the morning, with or without food. Maximum dose: 60 mg/day.
None Documented
None Documented
Clinical Note
moderateAminophylline + Gatifloxacin
"The metabolism of Gatifloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Rosoxacin
"The metabolism of Rosoxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Levofloxacin
"The metabolism of Levofloxacin can be decreased when combined with Aminophylline."
Clinical Note
moderateAminophylline + Trovafloxacin
Terminal elimination half-life: 3–12 hours in adults (mean ~6 hours); prolonged in hepatic impairment, heart failure, or COPD (up to 30 hours); shorter in smokers (4–5 hours due to CYP1A2 induction); neonates: 20–40 hours.
Terminal elimination half-life of vospire ER is approximately 12-15 hours. This prolonged half-life supports once-daily dosing and provides sustained bronchodilation over the dosing interval.
Renal excretion of unchanged drug accounts for ~10%, with the remainder eliminated as metabolites (caffeine, 3-methylxanthine, 1-methyluric acid, 1,3-dimethyluric acid) via urine; minimal biliary/fecal elimination (<5%).
Primarily renal (approximately 75% as unchanged drug and metabolites) and biliary/fecal (approximately 25%).
Category C
Category C
Xanthine Bronchodilator
Xanthine Bronchodilator
"The metabolism of Trovafloxacin can be decreased when combined with Aminophylline."